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Purpose of review: Until recently, management options in congenital 
cytomegalovirus infection (cCMV) have been either conservative or termination of 
pregnancy. However, medical therapies aimed at reducing the risk of infection and/or 
its severity have recently been investigated. 
 
Recent findings: In a phase 2 open label, non-randomised trial, valaciclovir was 
given to women carrying a CMV-infected fetus. Valaciclovir was associated with a 
greater proportion of asymptomatic neonates when compared with a historical cohort 
(82% vs 43%). However, the study design and the small number of treated women 
limit its applicability. Even though initial observational data suggested that 
hyperimmune globulin (HIG) therapy in pregnancy was associated with a significantly 
lower risk of cCMV, its efficacy has not been borne out in a subsequent phase 2 
randomised, placebo controlled, double blind study (cCMV 30% in the HIG group, 
44% in the placebo group (p=0.13)). Furthermore, 11% of fetuses in the HIG group 
had transient or permanent abnormalities, compared with 16% in the placebo group. 
 
Summary: Valaciclovir might have a promising role in the antenatal treatment of 
cCMV infection, but definitive recommendations require further research. The use of 
HIG should currently be limited to the research setting. 
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Cytomegalovirus (CMV) is the commonest cause of congenital infection, the leading 
non-genetic cause of sensorineural hearing loss (SNHL), the major infectious cause 
of infant malformation in developed countries and a major cause of neuro-disability 
[1,2]. It is estimated to account for up to 10% of cases of cerebral palsy [3]. The 
incidence of congenital CMV is estimated at 0.64%, while the incidence of 
symptomatic infection at birth is 0.07% [4-7]. Congenital CMV infection affects 40,000 
infants in the United States annually [8]. In the UK, 1-2 in every 200 neonates will be 
born with congenital CMV. Of these, around 13% will be symptomatic at birth, with a 
similar proportion developing problems later in childhood [9]. Moderate or severe 
outcomes were reported in 11% of children with congenital CMV identified through 





Because routine CMV screening does not meet several of the criteria for an effective 
screening test, not least the fact that there is no effective preventative treatment, in 
most countries it is not recommended outside of the research setting [10,11]. 
Currently, therefore, serological testing for CMV is offered only to women with 
influenza-like symptoms during pregnancy or in whom ultrasound detects fetal 
abnormalities suggestive of possible CMV infection. It is important to acknowledge a 
number of arguments that support routine screening during pregnancy: firstly, 
congenital CMV infection is more common than Down’s syndrome, which also has no 
treatment; secondly, if prevention is to be given an opportunity to be effective then 
screening is necessary; thirdly, the symptoms and ultrasound features lack 
specificity; fourthly, severe cases are more likely to be diagnosed, giving women the 
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option of possible termination if infection is identified and investigated. Focusing on a 
different setting, a UK cost analysis of targeted screening using salivary swabs 
integrated within the newborn hearing screening programme, with subsequent 
treatment for congenital CMV-related SNHL in otherwise asymptomatic infants, 
resulted in an estimated cost per case that compares favourably with other screening 
programmes [12]. Despite some compelling reasons for antenatal screening, 
congenital CMV does not adequately fulfill the criteria for the implementation of a 
screening programme.  
 
 
Pre-natal diagnosis of CMV infection is challenging and options for prevention and 
treatment are limited. The current approach to the antenatal management of 





There is no licensed vaccine for CMV nor is one likely for some time. An alternative 
strategy to reduce the risk of infection is behaviour modification in order to minimise 
contact with CMV. The primary source of CMV in pregnancy is the saliva and urine of 
infected young children, in whom viral shedding can persist for several years. Simple 
hygiene-based measures such as handwashing after contact with urine or saliva, and 
avoiding sharing utensils, drinks or food with young children can reduce the risk of 
CMV acquisition.  
 
Several studies have investigated such measures in pregnancy [13-16]; however, 
most have been underpowered or non-randomised. In a cluster randomised trial, 
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seronegative women with children under the age of three years were randomised to a 
day care centre that included information on hand hygiene and glove use or to one 
that did not. There was no difference in the seroconversion rates between the 
intervention and control groups. However, in the subgroup of women who had a child 
shedding CMV, those pregnant before enrolment had a significantly lower 
seroconversion rate than women attempting pregnancy (5.9% versus 41.7%; 
p=0.008) [14]. This suggests that such educational interventions to reduce CMV 
acquisition in pregnancy are more likely to be effective during pregnancy than before, 
probably because pregnant women are more motivated to adhere to these 
recommendations. In the most recent published study, seronegative women with a 
child less than 36 months received preventative information from a midwife or 
obstetrician in oral and written forms. The seroconversion rate in these women was 
1.2% compared to 7.6% in a group of pregnant women who did not receive such 
advice in pregnancy (p<0.001) providing further evidence that risk reduction is 
possible [16]. A study assessing the feasibility of an educational intervention to 
reduce the risk of congenital CMV in the UK (Reducing Acquisition of CMV through 





PRENATAL DIAGNOSIS AND PROGNOSIS 
 
Diagnosis of CMV infection in pregnancy is based on measurement of CMV-specific 
IgG and IgM immunoglobulins in the maternal blood. The presence of IgM is not 
diagnostic of recent primary CMV infection as IgM may persist for many months after 
the primary infection. IgM may also be detected during a secondary infection, and 
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there may be cross-reactivity with IgM due to another viral infection, e.g. Epstein Barr 
virus. Finally, IgM may be detected as a result of non-specific polyclonal stimulation 
of the immune system. IgG avidity testing is therefore often used in order to better 
define the timing of the infection (i.e. before or during pregnancy). Avidity levels are 
quantified by the avidity index which describes the proportion of IgG bound to the 
antigen following treatment with denaturing agents [17]. In general, a high avidity 
index (greater than 60%) is highly suggestive of past (greater than three months 
earlier) or secondary infection, while a low avidity index (less than 30%) is highly 
suggestive of recent primary infection (i.e. within the past three months) [18]. 
Maternal viraemia is a useful adjunct when suspecting seroconversion at 12 weeks 
[19]. Diagnosis of secondary CMV infection can be difficult. A rise in IgG levels does 
not confirm secondary infection as this rise may be due to non-specific polyclonal 
stimulation of the immune system. In practice, therefore, the only way of confirming 
secondary CMV infection is by invasive testing.  
 
Diagnosis of fetal infection is made by identification of the viral genome (DNA) by 
polymerase chain reaction (PCR), generally real time PCR, in the amniotic fluid 
following amniocentesis. Virus isolation has a higher specificity but lower sensitivity 
than PCR and is now rarely used. Depending on the virological method used, 
sensitivity ranges between 75% and 100%, with specificity between 67% and 100% 
[17,20-23]. Amniocentesis should not be performed before 20 weeks’ gestation when 
fetal urination is well established.  Furthermore, following primary maternal infection, 
the infective process will not lead to CMV excretion in the fetal urine until an average 
of 6-8 weeks later [24]; for this reason amniocentesis should be delayed until this 
point. In fact, most false negative amniocentesis results are likely to be attributed to 
the amniotic fluid being sampled too early in pregnancy or too early after the primary 
infection, and some studies suggest that when sampling conditions are ideal, the 
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sensitivity of prenatal diagnosis by PCR is close to 100% [24]. Occasionally false 
negatives may be explained by late transmission of the virus. One study found that 
8% of neonates with negative amniocentesis showed viral excretion at birth [25]; 
however, on follow-up none developed any sequelae. Because of the small risk of 
false positive and false negative PCR amniocentesis results, neonatal testing to 
confirm the diagnosis is essential [26,27]. 
 
Following prenatal diagnosis of fetal CMV infection, the main aim is to predict the risk 
of symptomatic neonatal infection, which is associated with poor outcome. Accurate 
prenatal prediction of poor prognosis for affected infants has proved challenging; 
estimates are based largely on three factors: 1. Timing of the infection; 2. Presence 
and type of fetal abnormalities; 3. Laboratory parameters. It appears that, in common 
with other viral infections, the risk of vertical transmission increases with gestation. 
However, the association between the timing of infection and severity of 
fetal/neonatal outcome is less well defined. As the diagnosis of congenital CMV 
infection is often incidental, severe ultrasound abnormalities are described more 
often than subtle findings. Ultrasound findings can be categorised as fetal cranial, 
fetal extracranial, and placenta/amniotic fluid abnormalities. It appears that the main 
sonographic prognostic indicator is fetal cerebral abnormalities [28]. Farkas et al 
reported that if the antenatal ultrasound examination of the fetal brain was normal, 
then normal early neuropsychological outcome was likely [28].  When both ultrasound 
and MRI of the fetal brain are normal prenatally, the neonatal outcome is generally 
good [29]. The combined predictive value of a normal ultrasound and MRI evaluation 
to predict an asymptomatic neonate, in fetuses with a positive amniocentesis and 
when imaging was performed up to the third trimester, after 30 weeks, is at best 95% 
[30]. Fetal laboratory findings, including viral load, thrombocytopenia (platelet count < 
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100,000/mm3) and raised alanine aminotransferase (>80 IU/ml) in the fetal blood may 
bridge this 5% gap.  
 
In a recent study the risk assessment of infected fetuses for being symptomatic at 
birth has been shown to be possible as early as the time of diagnosis; ultrasound 
abnormalities and either amniotic fluid viral load or fetal blood profile (viral load and 
platelet count) were independent prognostic factors of symptomatic congenital CMV 
at birth [31]. Both fetal platelet count and blood viral load were better predictors than 
amniotic fluid viral load. The combined negative predictive values of ultrasound and 
viral load in amniotic fluid and that of ultrasound and fetal blood parameters were 
95% and 100%, respectively [31]. Interestingly, when investigating the non-severe 
ultrasound features, the positive predictive values of ultrasound alone and in 
combination with amniotic fluid viral load or with fetal blood parameters were 60%, 





The aim of prenatal therapy is either to prevent mother-to-child transmission of CMV 
or to treat the CMV-infected fetus during pregnancy with the aim of reducing the risk 
of, and/or severity of, symptomatic infection in the infant.  
 
CMV hyperimmune globulin treatment to prevent antenatal mother-to-child 
transmission 
 
CMV human immunoglobulin (HIG) is a pooled, high-titre preparation derived from 
donors with high antibody titres. The rationale for its use is based on the observation 
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that primary maternal CMV infection carries a higher mother-to-child transmission risk 
(approximately 30%) compared to the risk in reactivation or reinfection (1.4%) [32]. Its 
role was investigated in two clinical trials [33,34] and two observational studies 
[35,36]. Nigro et al [33] conducted a non-randomised clinical trial using CMV HIG in 
women with a recent primary CMV infection and unknown fetal status before 21 
weeks’ gestation who declined amniocentesis; these women were offered monthly 
HIG 100 u/kg. Six of the 37 (16%) women who received HIG had neonates with 
congenital CMV infection compared to 19/47 (40%) women who did not receive HIG. 
Unfortunately, the efficacy of CMV HIG has not been borne out in a phase 2 
randomised placebo controlled double blind study [34]. This study included a total of 
124 women with primary CMV infection at 5 to 26 weeks’ gestation [34]. These 
women were randomly assigned within 6 weeks after the presumed primary infection 
to receive either HIG or placebo every 4 weeks until 36 weeks of gestation or until the 
detection of CMV in the amniotic fluid. The primary end-point was congenital infection 
diagnosed at birth or amniocentesis positive for CMV. The rate of congenital infection 
was 30% in the HIG group compared to 44% in the placebo group (a non-significant 
difference; p=0.13) [34]. This study found no significant difference between the two 
groups in the risk of transmission, the levels of virus specific antibodies, T cell 
mediated immune response or viral DNA in the blood. The clinical outcome of 
congenital infection at birth was similar in the two groups. However, the number of 
adverse obstetric events, including preterm birth, pre-eclampsia and intrauterine fetal 
growth restriction, was higher in the HIG group compared to the placebo group (13% 
versus 2%) [34].   
 
Given these conflicting findings, HIG is not routinely recommended and should 
currently be reserved for use in a research setting only. Another large phase III 
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randomized placebo-controlled double-blinded trial assessing HIG in pregnancy is 
currently underway (clinicaltrials.gov: NCT01376778). 
 
 
CMV hyperimmune globulin treatment to treat the CMV-infected fetus 
prenatally 
 
Four prospective and two retrospective studies treating small numbers of pregnant 
women diagnosed with congenital CMV infection have demonstrated a trend to 
efficacy using CMV HIG [33,35,37-40]. Nigro et al [33] conducted a non-randomised 
clinical trial in women with primary CMV whose amniotic fluid was positive for CMV; 
they were offered CMV HIG at a dose of 200 u/kg. Only 1/31 (3%) of neonates had 
symptomatic CMV disease compared with 7/14 (50%) of women not treated. The 
authors concluded that HIG therapy was associated with a significantly lower risk of 
congenital CMV infection, especially symptomatic infection. In the recent randomized, 
placebo-controlled double-blind trial by Revello et al [34], 7/61 (11%) fetuses of 
women treated with 100 IU/kg CMV HIG every 4 weeks had transient or permanent 
abnormalities, compared with 10/62 (16%) fetuses in the placebo group (a non-
significant trend). Based on these conflicting findings, HIG should not be 
recommended as antenatal treatment, and should currently be reserved for use in a 
research setting only. 
 
 
Antiviral treatment to prevent antenatal mother-to-child transmission 
 
A randomized, phase II double-blinded clinical trial is planned to evaluate the efficacy 
of valaciclovir (ValACV) to prevent mother-to-child transmission following primary 
maternal infection (clinicaltrials.gov identifier NCT02351102). The current use of 
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antiviral treatment to prevent mother-to-child transmission outside of the research 
setting is not recommended. 
 
 
Antiviral treatment to treat the CMV-infected fetus prenatally 
 
In immunocompromised (non-pregnant) patients, three anti-CMV drugs are licensed 
for use, namely ganciclovir, cidofovir and foscarnet, but their teratogenic and toxic 
effects preclude their use in pregnancy. Aciclovir (ACV) and its oral prodrug ValACV 
have been shown to have some effect against CMV in immunocompromised patients 
[41-43]. In a pilot observational study, Jacquemard et al treated pregnant women with 
primary CMV with oral ValACV 8g/day [44]. Twenty pregnancies with 21 fetuses were 
treated at 28 weeks’ gestation (range 22-34 weeks) for 7 weeks (range 1-12 weeks). 
Therapeutic concentrations of the drug were achieved in both maternal and fetal 
blood, and the viral load in fetal blood decreased significantly after 1 to 12 weeks of 
treatment. In terms of outcome, seven cases had termination of pregnancy and had 
evidence of in utero progression of the disease with worsening cerebral lesions, or 
died in utero. A further two infants had severe isolated unilateral deafness. One child 
had microcephaly with severe deafness but was also diagnosed with incontinentia 
pigmenti. The remaining 10 infants were developing normally at follow-up, at one to 
five years of age. By comparison, the outcomes of 24 untreated symptomatic CMV-
infected fetuses were as follows: 14 (58%) had termination of pregnancy, intrauterine 
fetal death or severe neonatal infection. The remaining 10 infants were healthy at 
follow-up.  
 
Oral ValACV was investigated in a recent open-label, single-group assignment phase 
II clinical trial entitled ‘in utero treatment of cytomegalovirus congenital infection with 
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valacyclovir (CYMEVAL) [45]. Oral ValACV 8g per day was given for a median of 89 
days to pregnant women carrying a moderately infected fetus (Table 1) [45]. When 
compared with a historical cohort obtained by a meta-analysis of the literature, 
ValACV significantly increased the proportion of asymptomatic neonates from 43% 
without treatment to 82% with treatment. This study also provided safety data for the 
use of valacyclovir in pregnancy [45]. However, the study design and the small 
number of ValACV-treated women are limitations, and therefore further studies are 
currently being planned (none listed in clinicaltrials.gov yet). 
 
 
A proposal for management of cytomegalovirus fetal infection is illustrated in Figure 
2. In neonates with symptomatic congenital CMV infection, there is a role for 
postnatal val/ganciclovir treatment, which should be commenced within the first four 
weeks of life. There is evidence that treatment can reduce or prevent progression of 





Antenatal oral ValACV might have a promising role in the antenatal treatment of 
congenital cytomegalovirus. The published findings on the role of HIG are conflicting, 
and therefore HIG is not recommended, and should currently be reserved for use in 







 Routine screening for congenital cytomegalovirus infection is not recommended 
outside the research setting. 
 
 There is currently no licensed vaccine against cytomegalovirus.  
 
 An alternative strategy for prevention of congenital cytomegalovirus infection is 
to reduce the risk of acquisition of CMV infection through modification of 
behavior, education of the pregnant women and the healthcare professionals. 
 
 When fetal cytomegalovirus infection has been confirmed by amniocentesis, an 
important role of prenatal management is to identify the fetuses at risk of 
symptomatic neonatal disease. 
 
 Antenatal oral valacyclovir appears promising in reducing the risk of 
symptomatic cytomegalovirus disease at birth in mild or moderately 
symptomatic fetuses. Due to the limitations of the quality of the evidence, 
more studies are needed. 
 
 HIG is not routinely recommended in view of the recent evidence of lack of 
effectiveness and potential harm, and should currently be reserved for use in 
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Table 1. Criteria to define moderately infected fetus, as defined by the inclusion 
criteria in the study by Leruez-Ville et al [45]. 
 
At least 1 extracerebral abnormality 
compatible with fetal CMV infection   
  Fetal growth restriction 
  Abnormal amniotic ﬂuid volume 
  Ascites and/or pleural effusion 
  Skin oedema 
  Hydrops 
  Placentomegaly >40mm 
  Hyperechogenic bowel 
  Hepatomegaly >40mm 
  Splenomegaly >30mm 
  Liver calciﬁcations 
And/or 1 isolated cerebral abnormality   
  
Moderate isolated ventriculomegaly ( 
<15mm) 
  Isolated cerebral calciﬁcation 
  Isolated intraventricular adhesion 
  Vasculopathy of lenticulostriate vessels 
And/or laboratory ﬁndings of 
generalised CMV infection in fetal 
blood   
  Fetal viraemia >3000 copies/mL 





Figure 1. Proposed approach to the antenatal management of Congenital CMV 
infection 
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